Abstract
Despite effective antiretroviral therapy (ART) in controlling HIV, people living with HIV (PLWH) often experience chronic inflammation, accelerated aging, and a heightened risk for age-related diseases. This review explores the potential of Intermittent Fasting (InF) as a non-pharmacological intervention for HIV patients. InF is theorized to mitigate chronic inflammation by promoting gut microbiome health, reducing microbial translocation, enhancing mitochondrial function, and modulating the kynurenine pathway. The evidence suggests that InF may improve insulin sensitivity, reduce fat accumulation, and protect against neurocognitive decline. While more research, particularly clinical trials in HIV patients, is needed to confirm the safety and efficacy of InF, its multifaceted influence on gut health, immune function, and neuroprotection makes it a promising approach for improving the long-term health and quality of life of individuals living with HIV.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
